Jasper Therapeutics(US:JSPR)2026-03-30 21:32Financial Performance - The company reported net losses of $75.8 million and $71.3 million for the years ended December 31, 2025 and 2024, respectively, with accumulated deficit reaching $316.7 million[462]. - Net loss increased by $4.5 million, from $71.3 million in 2024 to $75.8 million in 2025, a 6% increase[475]. - Interest income decreased by $3.3 million, from $5.1 million in 2024 to $1.7 million in 2025, a 66% decline[475]. - Total operating expenses rose by $7.6 million, from $76.2 million in 2024 to $83.9 million in 2025, a 10% increase[475]. - Net cash used in operating activities was $77.2 million for the year ended December 31, 2025, compared to $62.6 million in 2024[501]. - The accumulated deficit as of December 31, 2025, was $316.7 million, raising concerns about the company's ability to continue as a going concern[492]. - The company has significant future funding requirements to support ongoing operations and R&D initiatives[491]. Cash and Financing - Cash and cash equivalents stood at $28.7 million as of December 31, 2025, which is insufficient to fund ongoing operations for at least twelve months from the date of the report[463]. - Cash provided by financing activities was $34.2 million in 2025, primarily from stock issuance[505]. - The company raised approximately $27.5 million from an underwritten public offering, issuing 11,670,707 shares of common stock[489]. - The company filed a universal shelf registration statement allowing the sale of up to $263.5 million in various securities[487]. - As of December 31, 2025, the company had cash and cash equivalents of $28.7 million, with no outstanding debt[521]. - The company intends to maintain its portfolio of cash equivalents in institutional market funds composed of U.S. Treasury securities[521]. Research and Development - The Phase 1b/2a BEACON study in Chronic Spontaneous Urticaria (CSU) showed that 100% of participants at the 240mg dose level achieved complete responses through 8 weeks[449]. - In the updated data from the BEACON study, 89% of participants in the 240mg and 360mg single-dose cohorts achieved a complete response[451]. - The Phase 1b/2a SPOTLIGHT study in Chronic Inducible Urticaria (CIndU) reported that 93% of participants in the 40mg and 120mg cohorts achieved a clinical response[452]. - The ETESIAN study in asthma demonstrated a reduction in allergen-induced Late Asthmatic Response (LAR) with improvements of 10.4% at 6 weeks and 8.7% at 12 weeks compared to baseline[454]. - The company plans to focus exclusively on mast cell driven diseases, discontinuing other development programs including those related to severe combined immunodeficiency (SCID)[456]. - The company aims to become a fully integrated discovery, development, and commercial entity in the field of mast cell therapeutics, with plans to broaden its pipeline[457]. Expenses and Costs - Research and development expenses increased by $7.3 million, from $55.8 million in 2024 to $63.1 million in 2025, representing a 13% increase[476]. - Program costs rose by $7.3 million, from $34.3 million in 2024 to $41.6 million in 2025, a 21% increase, driven by higher costs in clinical programs[479]. - Clinical program expenses increased by $3.5 million for CRO expenses, from $13.9 million in 2024 to $17.4 million in 2025[481]. - General and administrative expenses increased by $0.4 million, from $20.4 million in 2024 to $20.8 million in 2025, a 2% increase[482]. - Personnel-related costs in research and development increased by $0.2 million, from $14.9 million in 2024 to $15.1 million in 2025[477]. - General and overhead costs in research and development decreased by $0.3 million, from $6.6 million in 2024 to $6.3 million in 2025[478]. - Stock-based compensation expense was $6.7 million and $6.6 million for the years ended December 31, 2025 and 2024, respectively[517]. Other Financial Information - The company has not declared or paid any dividends to date[516]. - The company is classified as a "smaller reporting company," allowing for reduced disclosure obligations[520]. - The company has not experienced material foreign currency transaction gains or losses to date[522]. - Inflation has not had a material effect on the company's consolidated financial statements[523]. - The company has not had a formal hedging program with respect to foreign currency[522]. - The change in fair value of warrant liability increased by $8.5 million, from $0 in 2024 to $8.5 million in 2025[475]. - Total other income increased by $3.1 million, from $5.0 million in 2024 to $8.1 million in 2025[483]. - Interest income decreased by $3.4 million, from $5.1 million in 2024 to $1.7 million in 2025, due to lower cash balances[483]. - The company expects to recognize $9.1 million of total unrecognized compensation expense over a remaining weighted-average period of 2.50 years[517].